# Chemomab (CMMB) — Earnings

CMMB · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/cmmb/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q3 2025 |
| Period end | Sep 30, 2025 |
| EPS actual | −$0.02 |
| EPS estimate | −$0.04 |
| EPS surprise | +60.00% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Nov 21, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1534248/000117891325003932/zk2534057.htm) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q3 2025 | Nov 21, 2025 | −$0.04 | −$0.02 | 60.00% | — | — |
| Q2 2025 | Aug 14, 2025 | −$0.04 | −$0.02 | 60.00% | — | — |
| Q1 2025 | May 15, 2025 | −$0.04 | −$0.03 | 30.00% | — | — |
| Q4 2024 | Mar 3, 2025 | −$0.04 | −$0.03 | 20.00% | — | — |
| Q3 2024 | Nov 14, 2024 | −$0.04 | −$0.04 | 0.00% | — | — |
| Q2 2024 | Aug 21, 2024 | −$0.04 | −$0.05 | -30.00% | — | — |
| Q1 2024 | May 9, 2024 | −$0.04 | −$0.06 | -40.00% | — | — |
| Q4 2023 | Mar 7, 2024 | −$0.08 | −$0.05 | 35.00% | — | — |
| Q3 2023 | Nov 9, 2023 | −$0.12 | −$0.07 | 43.33% | — | — |
| Q2 2023 | Aug 14, 2023 | −$0.16 | −$0.14 | 10.00% | — | — |
| Q1 2023 | May 11, 2023 | −$0.14 | −$0.16 | -14.29% | — | — |
| Q2 2022 | Aug 12, 2022 | −$0.72 | −$0.11 | 85.00% | — | — |
| Q1 2022 | May 12, 2022 | −$0.68 | −$0.09 | 87.06% | — | — |
| Q4 2021 | Mar 9, 2022 | −$0.41 | −$0.09 | 78.71% | — | — |
| Q3 2021 | Nov 12, 2021 | −$0.06 | −$0.05 | 13.33% | — | — |
| Q2 2021 | Aug 13, 2021 | −$1.06 | −$0.05 | 95.09% | — | — |
| Q1 2021 | May 13, 2021 | −$0.64 | −$0.04 | 93.75% | — | — |
| Q2 2020 | Aug 14, 2020 | −$7.04 | −$5.76 | 18.18% | — | — |
| Q1 2020 | May 7, 2020 | −$7.04 | −$6.40 | 9.09% | — | — |

## Frequently Asked Questions

### When did Chemomab (CMMB) last report earnings?

Chemomab last reported on Nov 21, 2025, covering fiscal Q3 2025.

### Did CMMB beat earnings estimates?

Yes. Chemomab reported EPS of −$0.02 for Q3 2025 against a −$0.04 estimate — a 60.00% beat.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).